Chronic Myelocytic Leukemia
Antisense drug targeting c-myb oncogene starts phase I trial in cancer
Published in Drug Week, November 17th, 2006
The new compound, known as G4460, uses antisense technology to target an oncogene known as c-myb that regulates key functions in cancer cells. Using an accelerated dosing schedule, this study will evaluate dosing regimens, safety, biologic activity, and down-regulation of c-myb in patients with advanced hematologic cancers. The clinical trial will be conducted using the General Clinical Research Center at the University of Pennsylvania, Philadelphia, PA. G4460 has been granted Orphan Drug Designation by the Food and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-11-17)
More Articles from Drug Week
- Amyotrophic Lateral Sclerosis
Avicena completes patient enrollment for ALS-08 phase II clinical trial - Drug Development
Avi presents successful data using Neugene antisense to alter drug metabolism in humans - Influenza Vaccine
Intranasal flu vaccine produces higher antibody responses in young children than injectable - Market Analysis
U.S. market for psoriasis therapeutics to surpass $9 billion by 2016 - Angiogenesis
Findings from Kyung-Hee University advance knowledge in angiogenesis - Arrhythmia Therapy
Research from Bico, Department of Statistics broadens understanding of arrhythmia therapy - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
